Lexicon Pharmaceuticals, Inc. (LXRX) saw its loss almost stable for the quarter ended Mar. 31, 2017. In the previous year period, the company reported a loss of $34.88 million, or $0.34 a share.

Revenue during the quarter surged 46.41 percent to $18.29 million from $12.49 million in the previous year period.

Operating loss for the quarter was $42.48 million, compared with an operating loss of $33.87 million in the previous year period.

"The first quarter was a transformative one for Lexicon marked by the approval and launch of XERMELO in the U.S. I am extremely proud of the extraordinary men and women at Lexicon who ensured that XERMELO was available to patients within days following approval," said Lonnel Coats, Lexicon's president and chief executive officer. "Eight weeks into the launch, we continue to make significant strides in providing access to XERMELO and communicating its benefits to patients. We are very pleased with the speed and depth of XERMELO adoption, which we believe is a reflection of the early positive feedback we have received from both patients and physicians. In addition, we continue to advance our robust pipeline of drug candidates and look forward to reporting on multiple milestones, including new data from our three Phase 3 sotagliflozin trials, starting this month."